# Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Source: https://onco.cc/trials/nct04513717/  
OnCo record `nct04513717` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin / leuprolide, Histrelin, Leuprolide, Relugolix and Triptorelin in Prostate cancer, run by NRG Oncology, active and no longer recruiting.

## Summary

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial is a phase 3 interventional study registered as NCT04513717 by NRG Oncology, with 2753 participants planned, started 2021-01-21 and due to reach its primary completion in 2033-12-31. Interventions recorded: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin. Conditions recorded: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8.

Linked to the drug Buserelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04513717
- Phase: 3
- Setting: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
- Sponsor: NRG Oncology
- Enrolled: 2753

## Sources

- ClinicalTrials.gov NCT04513717: https://clinicaltrials.gov/study/NCT04513717

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Apalutamide](https://onco.cc/drugs/apalutamide/), [Bicalutamide](https://onco.cc/drugs/bicalutamide/), [Buserelin](https://onco.cc/drugs/buserelin/), [Degarelix](https://onco.cc/drugs/degarelix/), [Flutamide](https://onco.cc/drugs/flutamide/), [Goserelin / leuprolide (ovarian function suppression)](https://onco.cc/drugs/goserelin/), [Histrelin](https://onco.cc/drugs/histrelin/), [Leuprolide (leuprorelin) and GnRH agonists](https://onco.cc/drugs/leuprolide/), [Relugolix](https://onco.cc/drugs/relugolix/), [Triptorelin](https://onco.cc/drugs/triptorelin/)

---
JSON: https://onco.cc/api/v1/entities/nct04513717.json